{"denoms":[{"counts":[{"groupId":"BG000","value":"319"},{"groupId":"BG001","value":"323"},{"groupId":"BG002","value":"642"}],"units":"Participants"}],"groups":[{"description":"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, and 10; doxorubicin hydrochloride IV over 1-15 minutes (or as per institutional policies up to 60-minutes) on days 1 and 2 and cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 5, and 9; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 7, and 11.\n\nCONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7, 8, 9, 10, 13, 14, 17, 18, 21, and 22; doxorubicin hydrochloride IV on days 1 and 2 in weeks 1 and 9; cyclophosphamide IV over 30-60 minutes on day 1 in weeks 1, 7, 9, 13, 17, and 21; and ifosfamide IV over 1 hour and etoposide IV over 1-2 hours on days 1-5 in weeks 3, 5, 11, 15, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 1 and 9.","id":"BG000","title":"Arm A (Combination Chemotherapy)"},{"description":"INDUCTION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 5, 6, 9, 10, 11 and 12; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1 and 9; cyclophosphamide IV over 15-30 minutes on days 1-5 in weeks 1 and 9, and over 30-60 minutes on day 1 of weeks 5 and 11; ifosfamide and etoposide as in arm A; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 5 and 11.\n\nCONSOLIDATION THERAPY: Patients receive vincristine sulfate IV on day 1 in weeks 1, 2, 7-10, 13-16, 19, and 20; topotecan hydrochloride IV over 30 minutes on days 1-5 in weeks 1, 7, and 15; cyclophosphamide IV over 15-60 minutes on days 1-5 in weeks 1, 7, and 15, and over 30-60 minutes on day 1 in weeks 9, 13, and 19; ifosfamide IV over 1 hour and etoposide IV over 1- 2 hours on days 1-5 in weeks 3, 5, 11, 17, and 21; and doxorubicin hydrochloride IV on days 1 and 2 in weeks 9,13, and 19. Patients received Dexrazoxane with doxorubicin hydrochloride in weeks 13 and 19.","id":"BG001","title":"Arm B (Combination Chemotherapy, Topotecan Hydrochloride)"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"272"},{"groupId":"BG001","value":"280"},{"groupId":"BG002","value":"552"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"47"},{"groupId":"BG001","value":"43"},{"groupId":"BG002","value":"90"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"0","upperLimit":"32","value":"13"},{"groupId":"BG001","lowerLimit":"0","upperLimit":"34","value":"13"},{"groupId":"BG002","lowerLimit":"0","upperLimit":"34","value":"13"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"145"},{"groupId":"BG001","value":"130"},{"groupId":"BG002","value":"275"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"174"},{"groupId":"BG001","value":"193"},{"groupId":"BG002","value":"367"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"44"},{"groupId":"BG002","value":"89"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"269"},{"groupId":"BG001","value":"275"},{"groupId":"BG002","value":"544"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"9"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"3"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"17"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"14"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"267"},{"groupId":"BG001","value":"280"},{"groupId":"BG002","value":"547"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"56"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"286"},{"groupId":"BG001","value":"286"},{"groupId":"BG002","value":"572"}]}],"title":"United States"},{"categories":[{"measurements":[{"groupId":"BG000","value":"17"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"37"}]}],"title":"Australia"},{"categories":[{"measurements":[{"groupId":"BG000","value":"14"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"27"}]}],"title":"Canada"},{"categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"4"}]}],"title":"New Zealand"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Saudi Arabia"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Region of Enrollment","unitOfMeasure":"Participants"}]}